Abstracts tagged "Administrative Data"

Abstract Number: 0457 • ACR Convergence 2023
Biologic Disease Modifying Antirheumatic Drug Use in Immune Checkpoint Inhibitor-Treated Cancer Patients with Rheumatoid Arthritis: Utilization and Overall Survival
Deanna Jannat-Khah¹, Jeffrey R Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne Bass⁵, ¹Hospital For Special Surgery, New York, NY, ²Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

Background/Purpose: There is a dearth of knowledge around the safety of biologic disease modifying antirheumatic drugs (bDMARDS) in immune checkpoint inhibitor (ICI)-treated rheumatoid arthritis (RA)…
Abstract Number: 1059 • ACR Convergence 2023
Identification of Patients with Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis Using Medicare Claims Data
Anne Bass¹, Fenglong Xie², Alexa Meara³, Deanna Jannat-Khah⁴ and Jeffrey Curtis², ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²University of Alabama at Birmingham, Birmingham, AL, ³The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Hospital For Special Surgery, New York, NY
Background/Purpose: Immune checkpoint inhibitor (ICI) associated inflammatory arthritis (ICI-IA) has been suggested to occur in approximately 3-6% of ICI-treated patients with cancer1 but most studies…
Abstract Number: 2137 • ACR Convergence 2023
Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics
Jeffrey Curtis¹, Fenglong Xie¹, Yuji Su², Patrick Stewart³ and Amy S. Mudano¹, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ³Illumination Health, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) have an increasing array of treatment options available, and new blood-based diagnostic…
Abstract Number: 0668 • ACR Convergence 2023
Increased Risk of Cancer in Patients with Systemic Sclerosis: A Population-based Study
Jiwon Hwang¹, Yeonghee Eun², Kyungdo Han³ and Joong Kyong Ahn², ¹Division of Rheumatology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon-si, South Korea, ²Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Department of Statistics and Actuarial Science, Soongsil University, Seoul, South Korea
Background/Purpose: Previous studies have shown an association between systemic sclerosis and cancer. However, because the disease is rare, large-scale studies are lacking, especially in Asians.…
Abstract Number: 1102 • ACR Convergence 2023
Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)
Amy S. Mudano¹, Jessica Ryan¹, Emily Holladay², Kathleen Methric³, Danielle Grauer⁴, Brian LaMoreaux³, Fenglong Xie¹ and Jeffrey R Curtis⁵, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Horizon Therapeutics, Deerfield, IL, ⁴Illumination Health, Boca Raton, FL, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL
Background/Purpose: Treatment of patients with gout can be complex and, given the episodic nature of gout attacks, gout patients may not always return for regular…
Abstract Number: 2240 • ACR Convergence 2023
Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi)
Aisha Vadhariya¹, Sarah Ross¹, Brenna Brady², Helen Varker², Anh Thu Tran² and Jessica A Walsh³, ¹Eli Lilly and Company, Indianapolis, IN, ²Merative, Cambridge, MA, ³Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: The treatment paradigm for psoriatic arthritis (PsA) has changed over the last two decades, with increasing numbers of therapy options that target a variety…
Abstract Number: 0718 • ACR Convergence 2023
Clinical and Economic Burden of Polymyalgia Rheumatica in Patients with an Inadequate Response to Glucocorticoids in a Real-World Setting
Jeffrey Curtis¹, Lita Araujo², Stefano Fiore², Sebastian Sattui³, John Stone⁴, Kerri Ford² and Fenglong Xie⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sanofi, Cambridge, MA, ³University of Pittsburgh, Pittsburgh, PA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ⁵Illumination Health, Hoover, AL
Background/Purpose: The burden of continuing glucocorticoids (GCs) in patients with polymyalgia rheumatica (PMR) who have an inadequate response (IR)to GCs has not been evaluated.Methods: An…
Abstract Number: 1103 • ACR Convergence 2023
Evaluation of Outcomes Following Discontinuation of Pegloticase Therapy
Emily Holladay¹, Amy S. Mudano², Fenglong Xie², Jingyi Zhang¹, Ted R Mikuls³, Brian LaMoreaux⁴, Lissa Padnick-Silver⁴ and Jeffrey Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Illumination Health, Hoover, AL, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁴Horizon Therapeutics, Deerfield, IL
Background/Purpose: Little is known about the long-term effects of pegloticase therapy or what urate-lowering therapy (ULT) patients subsequently receive when they discontinue pegloticase. This analysis…
Abstract Number: 2272 • ACR Convergence 2023
Age and Race-Based Differences in Emergency Department Utilization for Systemic Lupus Erythematosus in the United States
Rashmi Dhital¹, Ioannis Karageorgiou², Ashbina Pokharel³ and Kenneth Kalunian⁴, ¹UC San Diego, San Diego, CA, ²William Beaumont University Hospital, Troy, MI, ³William Beaumont University Hospital, Royal Oak, MI, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) frequently visit the emergency department (ED) due to the complex disease course. Previous research highlights infection and pain…
Abstract Number: 0742 • ACR Convergence 2023
Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes
Natalie McCormick¹, Chio Yokose², Na Lu³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a revolutionary second-line treatment for type 2 diabetes associated with lower risk of cardiovascular and all-cause mortality, heart failure,…
Abstract Number: 1129 • ACR Convergence 2023
Accuracy and Performance Characteristics of Administrative Codes for the Diagnosis of Autoinflammatory Syndromes: A Discovery and Validation Study
Saeyun Lee¹, Sujin Kim², Suzanne Segerstrom², Polly Ferguson¹ and Aleksander Lenert³, ¹University of Iowa Carver College of Medicine, Iowa City, IA, ²University of Kentucky, Lexington, KY, ³University of Iowa, Iowa City, IA
Background/Purpose: Autoinflammatory syndromes (AIS), a group of rare rheumatic diseases driven by the innate immune system, remain understudied due to the lack of prospective cohorts.…
Abstract Number: 2281 • ACR Convergence 2023
Epidemiology and Risk of Brain Abscess in Patients with Systemic Lupus Erythematosus in Taiwan: A Nationwide Population-based Study
Ke-Hung Lin¹, Tzu-Min Lin¹ and Chi-Ching Chang², ¹Taipei Medical University Hospital, Taipei, Taiwan, ²Taipei Medical University, Taipei, Taiwan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune systemic disorder with high morbidity and mortality. Although CNS infections account for only 0.53–2.25% of all infections…
Abstract Number: 0779 • ACR Convergence 2023
Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14,778 Patients from the French Health Insurance Database (SNDS)
Laura PINA VEGAS¹, Laetitia Penso², Emilie Sbidian³ and pascal claudepierre⁴, ¹Henri Mondor University Hospital (APHP), Rheumatology Department, Créteil, France, ²Université Paris Est Créteil, Créteil, France, ³Hôpital Henri Mondor, Université Paris Est Créteil, Créteil, France, ⁴Universitary Henri Mondor Hospital, Creteil, France
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous condition and sex differences in phenotypic presentation, disease trajectory, and treatment response have been reported. Nevertheless, it remains…
Abstract Number: 1166 • ACR Convergence 2023
Patients with COVID-19 and Polymyositis Inpatient Outcomes and Hospital Cost: Nationwide Inpatient Sample 2020
Emily He¹ and Vaneet Sandhu², ¹Loma Linda University Health, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA
Background/Purpose: During the COVID-19 pandemic, there were growing concerns regarding the impact of SARS-CoV-2 on not only patients with rheumatic diseases but also the national…
Abstract Number: 2324 • ACR Convergence 2023
Leveraging ChatGPT for Real-World Systematic Lupus Erythematosus Data Curation from Electronic Health Records: A Feasibility Study
Lixia Yao, Liwam Gebru, Biruk Aweke, Jay Patel, Ernest Vina, David Fleece and Huanmei Wu, Temple University, Philadelphia, PA
Background/Purpose: Epidemiologists, health services researchers, and health outcome investigators have begun utilizing real-world data (RWD) to gain valuable insights into disease patterns, treatment outcomes, and…

« Previous Page
1
…
5
6
7
8
9
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].